Journal article
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
Jun Guo, Jie Jin, Mototsugu Oya, Hirotsugu Uemura, Shunji Takahashi, Katsunori Tatsugami, Sun Young Rha, Jae-Lyun Lee, Jinsoo Chung, Ho Yeong Lim, Hsi Chin Wu, Yen Hwa Chang, Arun Azad, Ian D Davis, Marlene J Carrasco-Alfonso, Bhupinder Nanua, Jackie Han, Qasim Ahmad, Robert Motzer
Journal of Hematology & Oncology | BIOMED CENTRAL LTD | Published : 2018
Grants
Awarded by Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship
Awarded by Memorial Sloan Kettering Cancer Center
Funding Acknowledgements
Financial support for this study was provided by GlaxoSmithKline Pharmaceuticals, Philadelphia, Pennsylvania; pazopanib is an asset of Novartis AG as of March 1, 2015. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. Ian D. Davis is supported by an Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship (APP1102604). Patients treated at Memorial Sloan Kettering Cancer Center were supported in part by Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748).